Credit Suisse Group reissued their buy rating on shares of Zoetis (NYSE:ZTS) in a report published on Wednesday morning, AnalystRatings.com reports. They currently have a $130.00 price objective on the stock.
Other research analysts have also issued reports about the stock. Goldman Sachs Group initiated coverage on shares of Zoetis in a report on Monday, September 9th. They issued a conviction-buy rating and a $145.00 price target for the company. Guggenheim initiated coverage on shares of Zoetis in a report on Thursday, May 23rd. They issued a buy rating and a $114.00 price target for the company. SunTrust Banks lifted their price target on shares of Zoetis from $120.00 to $130.00 and gave the company a hold rating in a report on Tuesday, August 13th. Argus set a $140.00 price target on shares of Zoetis and gave the company a buy rating in a report on Wednesday, September 4th. Finally, Barclays lifted their price objective on shares of Zoetis from $120.00 to $135.00 and gave the company an overweight rating in a research report on Wednesday, August 7th. Seven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $120.31.
NYSE ZTS opened at $121.02 on Wednesday. Zoetis has a one year low of $78.90 and a one year high of $130.08. The company has a 50-day simple moving average of $122.83 and a 200-day simple moving average of $108.92. The company has a debt-to-equity ratio of 2.74, a quick ratio of 2.87 and a current ratio of 4.17. The firm has a market capitalization of $57.64 billion, a PE ratio of 38.66, a price-to-earnings-growth ratio of 3.05 and a beta of 0.87.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.08. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.51 billion. During the same period in the previous year, the business posted $0.77 EPS. The company’s quarterly revenue was up 9.3% on a year-over-year basis. Equities analysts forecast that Zoetis will post 3.57 earnings per share for the current year.
In related news, EVP Kristin C. Peck sold 11,500 shares of Zoetis stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $123.22, for a total value of $1,417,030.00. Following the sale, the executive vice president now directly owns 48,877 shares in the company, valued at approximately $6,022,623.94. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Roxanne Lagano sold 4,463 shares of Zoetis stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $125.99, for a total transaction of $562,293.37. Following the completion of the sale, the executive vice president now owns 33,190 shares in the company, valued at $4,181,608.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,209 shares of company stock worth $3,428,025. 0.29% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of the stock. Glassman Wealth Services raised its position in shares of Zoetis by 306.5% during the 1st quarter. Glassman Wealth Services now owns 252 shares of the company’s stock worth $25,000 after buying an additional 190 shares in the last quarter. JJJ Advisors Inc. bought a new stake in shares of Zoetis during the 2nd quarter worth about $25,000. Private Ocean LLC bought a new stake in shares of Zoetis during the 1st quarter worth about $27,000. Prestige Wealth Management Group LLC bought a new stake in shares of Zoetis during the 2nd quarter worth about $27,000. Finally, Altshuler Shaham Ltd raised its position in shares of Zoetis by 198.8% during the 2nd quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock worth $29,000 after buying an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 90.25% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: Dead Cat Bounce